Epcoritamab
- Generic Name
- Epcoritamab
- Brand Names
- Epkinly, Tepkinly
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2134641-34-0
- Unique Ingredient Identifier
- D6OMY2L0WA
- Background
Epcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells. Epcoritamab promotes the activation and expansion of T-cells and, by being able to bind to both CD20 and CD3, it leads to the T-cell–mediated killing of CD20+ malignant B cells. Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of cancer comm...
- Indication
Epcoritamab is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under acc...
- Associated Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Associated Therapies
- -
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 34
- Registration Number
- NCT06723457
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
- Conditions
- Interventions
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 30
- Registration Number
- NCT06676033
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
- Conditions
- Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderEBV-Related Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative DisorderRecurrent Polymorphic Post-Transplant Lymphoproliferative DisorderRefractory Monomorphic Post-Transplant Lymphoproliferative DisorderRefractory Polymorphic Post-Transplant Lymphoproliferative Disorder
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Timothy Voorhees
- Target Recruit Count
- 26
- Registration Number
- NCT06672705
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT06575686
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
Epcoritamab, Zanubrutinib, and Rituximab (EZR) for R/R FL Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Reid Merryman, MD
- Target Recruit Count
- 24
- Registration Number
- NCT06563596
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Epcoritamab in Previously Treated WM
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Gottfried von Keudell, MD PhD
- Target Recruit Count
- 20
- Registration Number
- NCT06510491
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Epcoritamab in Patients with Follicular Lymphoma Not Accomplishing a CR with Upfront Chemoimmunotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 35
- Registration Number
- NCT06510361
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 360
- Registration Number
- NCT06508658
- Locations
- 🇦🇺
Toowoomba Hospital /ID# 263243, Toowoomba, Queensland, Australia
🇧🇪Universitair Ziekenhuis Brussel /ID# 242574, Jette, Bruxelles-Capitale, Belgium
🇧🇪AZ-Delta /ID# 264740, Roeselare, West-Vlaanderen, Belgium
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 31
- Registration Number
- NCT06458439
- Locations
- 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Paolo Caimi, MD
- Target Recruit Count
- 20
- Registration Number
- NCT06447376
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.